Cite
Different lymphocyte counts of multiple sclerosis patients treated with ofatumumab and ocrelizumab: A retrospective observational study.
MLA
Friedli, Christoph, et al. “Different Lymphocyte Counts of Multiple Sclerosis Patients Treated with Ofatumumab and Ocrelizumab: A Retrospective Observational Study.” Journal of Central Nervous System Disease, vol. 16, May 2024, p. 11795735241249644. EBSCOhost, https://doi.org/10.1177/11795735241249644.
APA
Friedli, C., Krajnc, N., Hammer, H. N., Marti, S., Zrzavy, T., Evangelopoulos, M. E., Kapsali, I., Rommer, P., Berger, T., Chan, A., Bsteh, G., & Hoepner, R. (2024). Different lymphocyte counts of multiple sclerosis patients treated with ofatumumab and ocrelizumab: A retrospective observational study. Journal of Central Nervous System Disease, 16, 11795735241249644. https://doi.org/10.1177/11795735241249644
Chicago
Friedli, Christoph, Nik Krajnc, Helly N Hammer, Stefanie Marti, Tobias Zrzavy, Maria E Evangelopoulos, Ioanna Kapsali, et al. 2024. “Different Lymphocyte Counts of Multiple Sclerosis Patients Treated with Ofatumumab and Ocrelizumab: A Retrospective Observational Study.” Journal of Central Nervous System Disease 16 (May): 11795735241249644. doi:10.1177/11795735241249644.